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Down-regulation of the tumor suppressor
miR-34a contributes to head and neck
cancer by up-regulating the MET oncogene
and modulating tumor immune evasion
Xun Wu1,2,3, Yi-Shing Lisa Cheng4, Mathew Matthen5, Angela Yoon6, Gary K. Schwartz5, Shashi Bala7,
Alison M. Taylor8,9* and Fatemeh Momen-Heravi1,2,8*
Abstract
Background: MicroRNAs (miRs) have been shown to play an important role in tumorigenesis, including in head
and neck squamous cell carcinoma (HNSCC). The miR-34 family is thought to play a role in tumor suppression, but
the exact mechanism of their action in HNSCC is not well understood. Moreover, the impact of chromosomal
changes and mutation status on miR-34a expression remains unknown.
Methods: Differential expression of miR-34a, MET, and genomic alterations were assessed in the Cancer Genome
Atlas (TCGA) datasets as well as in primary HNSCC and adjacent normal tissue. The biological functions of miR-34a
in HNSCC were investigated in samples derived from primary human tumors and HNSCC cell lines. The expression
of MET was evaluated using immunohistochemistry, and the molecular interaction of miR-34a and MET were
demonstrated by RNA pulldown, RNA immunoprecipitation, luciferase reporter assay, and rescue experiments.
Lastly, locked nucleic acid (LNA) miRs in mouse xenograft models were used to evaluate the clinical relevance of
miR-34a in HNSCC tumor growth and modulation of the tumor microenvironment in vivo.
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Results: Chromosome arm 1p loss and P53 mutations are both associated with lower levels of miR-34a. In HNSCC,
miR-34a acts as a tumor suppressor and physically interacts with and functionally targets the proto-oncogene MET.
Our studies found that miR-34a suppresses HNSCC carcinogenesis, at least in part, by downregulating MET,
consequently inhibiting HNSCC proliferation. Consistent with these findings, administration of LNA-miR-34a in an
in vivo model of HNSCC leads to diminished HNSCC cell proliferation and tumor burden in vitro and in vivo,
represses expression of genes involved in epithelial-mesenchymal transition, and negates the oncogenic effect of
MET in mouse tumors. Consistently, LNA-miR-34a induced a decreased number of immunosuppressive PDL1-
expressing tumor-associated macrophages in the tumor microenvironment. In HNSCC patient samples, higher levels
of miR-34a are significantly associated with a higher frequency of Th1 cells and CD8 naïve T cells.
Conclusions: Our results demonstrate that miR-34a directly targets MET and maintains anti-tumor immune activity.
We propose miR-34a as a potential new therapeutic approach for HNSCC.
Keywords: Head and neck cancer, miR-34a, Aneuploidy, P53, MET, micoRNA
Background
MicroRNAs (miR) are evolutionarily conserved non-
coding RNAs that play roles in fundamental cellular
functions by post-translational suppression of gene ex-
pression [1]. In cancer pathogenesis, miRs can exert both
anti-tumorigenic and pro-tumorigenic effects by virtue
of miR-specific and context-dependent mechanisms.
The miR-34 family is considered one of the regulators of
tumor suppression [2]. In mammals, the miR-34 family
includes three miRs that are encoded by two different
genes. miR-34a is encoded by its own transcript, while
miR-34b and miR-34c share a common transcript and
are dysregulated in some cancers [3]. Decreased levels of
miR-34a expression have been reported in and linked to
the pathogenesis of numerous types of cancer, including
ovarian cancer, colorectal cancer, pediatric neuroblast-
oma, hepatocellular carcinoma, triple-negative breast
cancer, lung adenocarcinomas, bladder cancer, prostate
cancer, and osteosarcoma [4–12]. The locus harboring
the miR-34a transcripts is in a region associated with a
chromosomal fragile site on chromosome 1p. The 1p
chromosome arm is frequently deleted in many cancers,
including squamous cancers [13].
Recent findings showed that transcription of the miR-
34 family is controlled by the tumor suppressor p53
[14–16]. p53 has multiple binding sites in regions prox-
imal to the MIR34A promoter [17, 18]. Other gene regu-
latory mechanisms, such as CpG methylation of the
MIR34A promoter, have been reported as the main
causes of miR-34a down-regulation [19]. Mechanistic
studies demonstrated that miR-34a itself is a key player
in the p53 network, mediating the biological function of
p53 by regulating the expression of different genes [20].
miR-34a directly suppresses HDM4, a negative regulator
of p53, forming a positive feedback loop acting on p53
[21]. Treatment with a miR-34a inhibitor attenuates
p53-mediated apoptosis in response to genotoxic stress,
whereas the ectopic expression of miR-34a causes a
significant reprogramming of gene expression and in-
duces apoptosis and cell cycle arrest [22]. miR-34a has
been shown to directly target the 3′ untranslated regions
(UTRs) of numerous mRNAs with roles in oncogenesis
beyond p53, including Bcl-2, PIK3R2, c-Myc, SIRT1,
VAMP2, IKBKE, MYH9, KLRK1, CD11A, SDK4–6,
Notch1, TRAFD1, and CCR1 [23–26], which may con-
tribute to its tumor-suppressive function.
In head and neck squamous cell carcinoma (HNSCC),
miRs can serve as biomarkers for diagnosis and progno-
sis [27, 28]. Reduction of miR-34a was detected in
HNSCC cell lines and tumor tissues and was associated
with cell proliferation and angiogenesis [29]. However,
the genetic alterations and molecular network that cause
miR-34a downregulation in HNSCC are not well under-
stood. Moreover, the mechanistic role of miR-34a down-
regulation in the pathogenesis of HNSCC and the tumor
microenvironment is not well established.
Our bioinformatics and experimental analyses identi-
fied several genes, including the MET proto-oncogene,
that are directly regulated by miR-34a. This regulation
has implications for the role of miR-34a in suppressing
tumor growth and modulating the tumor microenviron-
ment. MET is a receptor tyrosine kinase [30], deregu-
lated in many types of human malignancies including
breast cancer, lung cancer, bladder cancer, hepatocellu-
lar carcinoma, and melanoma [31, 32]. Although abnor-
mal activation of MET in some cancers, such as
hepatocellular carcinoma, is known to be correlated with
poor prognosis [33], the role of the miR-34a-MET axis
in HNSCC has not been investigated. Additionally, the
role of miR-34a in the tumor microenvironment in
HNSCC is also yet to be elucidated. miR-34a based ther-
apeutics have been brought to melanoma clinical trials
as a first-in-class miR therapy (https://clinicaltrials.gov/
ct2/show/NCT02862145) [34], but this has not been ex-
plored in HNSCC. In the present study, we determined
that miR-34a suppresses HNSCC growth by inducing
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cell cycle arrest and senescence, and we identified an
anti-tumor miR-34a regulatory function in HNSCC and
tumor-associated macrophages (TAMs) in vivo.
Methods
TCGA samples
Our analysis included the TCGA pan-cancer atlas data-
set, which includes 10,522 tumors across 33 cancer types
including 528 HNSCC samples. The following data is
available at gdc.cancer.gov/node/977: cancer type, p53
mutation status, chromosome arm aneuploidy status,
miR-34a expression, and mRNA gene expression. Only
samples with both miR expression profiling and muta-
tion or mRNA expression profiling were considered.
Correlation between miR-34a and MET mRNA was
quantified with Pearson’s correlation coefficient, and
correlation coefficients with Bonferroni-corrected p-
value ≤0.05 were considered statistically significant. The
Mann-Whitney U test was used to compare expression
between different groups of samples. We generated sur-
vival curves of HNSCC cases in the TCGA- cohort ac-
cording to the expression status of the MET gene
stratified based on HPV status. A group cutoff of “quar-
tile” was identified, and the Kaplan–Meier curve was
plotted. Univariate and multivariable Cox proportional
hazards regression was used to assess association with
overall survival controlling for different covariates using
R software. Estimation of individual immune subtype
fractions by xCell in TCGA samples is publicly available
at xcell.ucsf.edu.
Gene set enrichment analysis (GSEA)
First, within the HNSCC samples of the TCGA, we per-
formed Pearson correlations to identify genes whose ex-
pression correlates with miR-34a expression. Genes that
correlated with miR-34a expression with a Bonferroni
corrected p-value of < 0.01 were analyzed by the GSEA
pre-ranked algorithm to look for enrichment of these
genes in the GSEA hallmark datasets.
Clinical samples
Clinical samples and plasma were obtained from the
Tumor Bank of Columbia University Irving Medical
Center, Biomarker Core of Herbert Irving Comprehen-
sive Cancer Center, and University of Massachusetts
Medical School Conquering Diseases Biorepository. All
samples were collected based on an institutional review
board guideline. Forty-two histologically confirmed
HNSCC samples from a Columbia HNSCC cohort were
included in this study, with 80% tumor contact in each
sample. The cohort demographics were the following: 26
males, 16 females; age, mean standard deviation (SD) of
64 (6.3) years. 55% of patients were stage I and II, and
45% were stage III and IV HNSCC. Plasma samples were
obtained from 14 HNSCC patients and 14 age- and sex-
matched healthy controls. The mean (SD) of the age of
HNSCC was 62 (5.2) years, and the mean (SD) age of
healthy controls was 60 (6.1). There were five females
and nine males in each group.
In vitro pull-down assay
miR-34a-5p biotin labeled probe was synthesized by IDT
with the probe sequence of 5’Biotin-TGG CAG TGT
CTT AGC TGG TTG T as well as the negative control
probe with the sequence of 5’Biotin-ACG TGA CAC
GTT CGG AGA ATT. RNA samples isolated from
CAL27 cells using TRI reagent (Zymo) and treated with
DNase I according to the manufacturer’s instructions.
Biotin-labeled miR-34a-5p pull-down probe or a nega-
tive control probes in the final volume of 100ul and con-
centration of 1, 0.5, or 0.25 uM were used. 20 μg of
RNA was incubated with probe for 1 h at 4 °C. A
μMACS separator (Miltney) was used for purification
following the manufacturer’s protocol. The levels of
pulled-down MET were quantified by a real-time RT-
PCR assay and normalized to the total input.
Absolute quantification of miR-34a-5p and miR-34a-3p
Synthetic cel-miR-39, miR-34a-5p mimic, and miR-34a-
3p mimic (Applied Biosystem) were serially diluted to
final concentrations of 300 nM, 30 nM, 3 nM, 0.3 nM,
0.03 nM, 3 pM, 0.3 pM, 0.03 pM, 3 fM, and 0.3 fM.
miR-34a-5p, miR-34a-3p, and cel-miR-39 serial dilutions
were reverse-transcribed and assayed using real-time
PCR analysis concurrently with RNA extracted from
tumor samples and normal tissue. 2.5 μL of exogenous
cel-miR-39 at a concentration of 200 amol/μl was intro-
duced as an exogenous normalizer before RNA extrac-
tion in all samples. Standard curves for miR-34a-5p and
miR-34a-3p and cel-miR-39 were included on each plate
of the TaqMan microRNA assays to convert the Ct
values of each sample into the corresponding number of
microRNA copies. The absolute quantification result of
miR-34a-5p and miR-34a-3p was obtained by
normalization to cel-miR-39.
Tumor model
All experimental procedures were approved by Institu-
tional Animal Care and Use Committees. Six-week old
female nude mice (NU/J) were purchased from Jackson
Laboratories. The animals were subjected to a 12 h light
cycle, relative humidity of 55%, and temperature of 21 ±
2 °C. After one week of adaptation, animals were inocu-
lated with HTB-43 tumor cells (2 × 106 cells in 100ul
volume of PBS) in tongue. HTB-43 xenograft model in-
duces aggressive HNSCC tumors [35]. Tumor volume
was measured continuously from day 4 post implant to
following the development of tumors. Ten days post
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implantation of tumor cells, 24 mice were randomized
to three group of control (PBS injection), LNA- miR-
34a-5p or LNA-miR-34a-5p (n = 8 per group; n = 24
total). Mice were dosed with LNA- control mimic or
LNA-miR-34-mimic (20 mg/kg/ intraperitoneal (i.p))
every week for two weeks at day 10 post tumor injection.
Tumor volume measurements were quantified by digital
calipers and calculated using the formula (π)/6 × (large
diameter) × (small diameter)2. The mice were anesthe-
tized by CO2 chamber (70% CO2/30% O2) and cervical
dislocation. No adverse events and change in the mice
well-being were observed in any of the treatment groups.
Tumors were retrieved from animals and went through
tumor dissociation protocol for flow cytometry analysis
or single cell isolation using a gentleMACS™ Tissue dis-
sociator (Miltenyi) and tumor dissociation kit (Miltenyi)
as recommended by the manufacturer. Anti-EpCAM
magnetic beads (Miltenyi) were used for isolation of
squamous epithelial tumor cells. CD11b magnetic beads
(Miltenyi) were used for isolation of TAMs after tumor
dissociation as recommended by the manufacturer. Sec-
tions of tumors were kept in RNAlater® for RNA isola-
tion or stored at − 80 °C for protein analysis.
Plasmid construction and luciferase reporter assay
The 3′-untranslated region (UTR) of human MET and
PDL1 were amplified from human genomic DNA and
individually inserted into the pmirGLO Dual-Luciferase
miRNA Target Expression Vector. Mutant PDL1 and
MET 3′-UTRs were generated with the QuickchangeXL
mutagenesis kit (Stratagene, United States) to disrupt
the binding of miR-34a. The fragment of MET and
PDL1 3′-UTR mutant was inserted into the pmirGLO
Dual-Luciferase miR Target Expression Vector. CAL27
cells were co-transfected with wild-type or mutant MET
reporter plasmid and miR-34a-5p mimic or negative
control using Lipofectamine 2000 (Invitrogen). Similar
approach was taken to verify interaction of miR-34a-5p
with PDL1 3’UTR in RAW macrophages. Luciferase ac-
tivity was measured forty-eight hours post-transfection
using Dual-Glo Luciferase Reporter System according to
the manufacturer’s instructions (Promega) using a
LB96V luminometer (Berthold). Firefly luciferase units
were normalized against Renilla luciferase units to con-
trol for transfection efficiency. Luciferase activity was av-
eraged from at least 5 replicates.
Immunohistochemistry
Paraffin-embedded human-epithelial tissues, HNSCC tis-
sues, and dysplastic oral squamous cell tissues were im-
munostained for MET protein using a laboratory
established protocol. Briefly, deparaffinization, sequential
ethanol treatment and antigen retrieval was performed.
The process was followed by blocking and inactivating
endogenous peroxidase with 3% H2O2, addition of the
primary antibody (overnight; 4 °C) and addition of
biotin-labeled secondary antibody (Room temperature;
30 mins). DAB was used for staining. Slides were digit-
ally imaged at 20X magnification and analyzed within
the Aperio Spectrum Database.
Western blot
Western blots were performed using the following estab-
lished laboratory protocols. Cells were lysed in RIPA
buffer and protein was quantified using a Bradford assay
(Thermofisher). Proteins were separated using 10% SDS-
PAGE electrophoresis and transferred onto polyvinyli-
dene difluoride (PVDF) membranes. The membranes
were blocked with 5% nonfat milk and incubated at 4 °C
overnight with MET, Vimentin, CDH1, GAPDH, and
Actin antibodies (1:1000). The membranes were then re-
incubated with anti-rabbit (1:5000) secondary peroxidase-
labeled antibodies at room temperature for 2 h. The blots
were visualized with ECL Plus reagent (Bio-Rad).
Exosome isolation
Exosomes were extracted from plasma using an estab-
lished protocol. Plasma samples were centrifuged at
1500 g for 10 min at 4 °C to remove the cellular debris
and then at 10,000 g for 20 min to remove the large vesi-
cles. The supernatant was collected and incubated with
ExoQuick™ overnight at 4 °C. The mixture was centri-
fuged twice at 1500 g for 30 min to pellet the exosomes.
The pellet was finally resuspended in 200 μl of PBS and
used for RNA isolation. For the isolation of exosomes
from THP-1 culture medium, supernatants were centri-
fuged at 700 g for 15 mins to deplete cells and then at
12,000 g for 30 mins to eliminate residual cellular debris,
as described previously. The resulting supernatant was
passed through 0.4 μm and 0.22 μm filters and concen-
trated using the Amicon Ultra-15 Centrifugal Filter Unit
with Ultracel-100 membrane (Millipore).
RNA isolation
RNA from cells, exosomes, and plasma was isolated
using a QIAzol Lysis reagent and total RNA was isolated
using Direct-zol™ RNA MiniPrep isolation kit (Zymo Re-
search). 100 μL of exosome suspension or plasma from
plasma of patients with HNSCC or healthy subjects were
mixed with 300 μL QIAzol lysis buffer, and the mixture
was processed according to the standard protocol.
Quantity and quality of the RNA were determined by
NanoDrop 1000 (260/280 and 260/230 ratios).
Quantitative reverse transcription PCR (qRT-PCR)
Quantitative Reverse Transcription PCR (qRT-PCR) was
used to determine the expression levels of mRNAs. For
mRNA analyses, cDNA was transcribed from 1 μg of
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total RNA utilizing iScript™ cDNA synthesis kit (Bio-
Rad). Real-time quantitative PCR was performed with
iTaq Universal SYBR Green Supermix (Bio-Rad). The
primer sequences were as follows: human MET (for-
ward), 5′-GAG GCA GTG CAG CAT GTA GT-3′, hu-
man MET (reverse), 5′-GAT GAT TCC CTC GGT
CAG AA-3′, GAPDH (forward), 5′-TCA GTG GTG
GAC CTG ACC TG-3′, GAPDH (reverse), 5′-TGC
TGT AGC CAA ATT CGT TG-3′. mouse MET (for-
ward), 5′-GACTTCAGCCATCCCAATGT-3′, mouse
MET (reverse), 5′-GGTGAACTTCTGCGTTTGC-3′.
human Vimentin (forward), 5′-TGTCCAAATCGATG




TCCG-3′, mouse Vimentin (forward) 5′-CCCTCACC
TGTGAAGTGGAT-3′, mouse Vimentin (reverse) 5′-
TCCAGCAGCTTCCTGTAGGT − 3′. mRNA relative
levels were calculated using the ΔΔCt method. The rela-
tive expression level of each mRNA was presented by
2–ΔΔCt.
microRNA analysis
TaqMan microRNA Assays (Applied Biosystems) was
used for detection of miR-34a-3p and miR-34a-5p ex-
pression according to manufacturer’s protocol. Briefly,
reverse transcription (30 min, 16 °C; 30 min, 42 °C; 5 min
85 °C) was performed using a TaqMan stem loop primer,
15 ng RNA, TaqMan primers and miR reverse transcrip-
tion kit (Applied Biosystems). qRT- PCR was performed
using the TaqMan Universal PCR Master Mix according
to the manufacturer’s protocol. RNU-48 was used to
normalize the Ct values between the samples. In experi-
ments involving miR analysis of exosomes or plasma,
synthetic C. elegans (cel)-miR-39 was spiked during the
total RNA isolation process and used as normalizer. All
experiments were performed in triplicate. miR levels
were normalized and the relative expression levels of
specific miR were presented by 2–ΔΔCt.
MTT assay
CAL27 or HTB-43 cells were plated in 96-well plates.
After 24 h, transfection with 25 nM of miR-34a-5p
mimic or control mimic (Ambion) was performed with
Lipofectamine RNAiMAX (Thermofisher). 3-(4,5-Di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay was performed using the Vybrant® MTT Cell
Proliferation Assay Kit, as described by the manufac-
turer. The absorbance of the samples was measured
at 595 nm using a microtiter plate reader. Experi-
ments were assayed in triplicate.
Apoptosis detection assay
Apoptosis levels were measured using an Annexin A5
apoptosis detection Kit (BioLegend) according to the
manufacturer’s protocol. HTB-43 and CAL27 cells were
pretreated with miR-34a-5p mimic using electroporation
as described by our group previously [36]. Cells were
collected after 48 h and the treated cells were washed
twice with cold BioLegend’s Cell Staining Buffer and
then resuspended in Annexin V Binding Buffer at a con-
centration of 0.25–1.0 × 10 cells/mL. After incubating
for 15 min (25 °C), the cells were subjected to flow cy-
tometry analysis to detect the apoptosis.
Antibodies and reagents
The following primary antibodies were used for this study:
MET monoclonal antibody (3D4) (37–0100; Invitrogen);
Ago2 Monoclonal Antibody (MA5–23515, Invitrogen);
mouse IgG (sc-2025; Santa Cruz); FITC anti-STAT3
Phospho (Tyr705) (Biolegend); anti-mouse CD45 Anti-
body (30-F11, Biolegend); anti mouse MET antibody
(ab51067, Abcam); anti-mouse CD11b Antibody (M1/70,
Invitrogen); anti-mouse F4/80 Antibody (BM8; Biolegend);
anti-mouse lineage cocktail (145-2C11; RB6-8C5; RA3-
6B2; Ter-119; M1/70; Biolegend) and anti-mouse CD274
(PDL1) (10F.9G2; Biolegend), and anti-mouse Vimentin
APC-conjugated Antibody (IC2105A, &D). hsa-miR-34a-
5p mimic and inhibitors were obtained from Ambion
(Thermofisher). pLL3.7 was a gift from Luk Parijs
(Addgene plasmid # 11795). pLL3.7 miR-34a-5p was a gift
from Judy Lieberman (Addgene plasmid # 25791). The
MET vector used in this study included both coding se-
quence and 3’UTR of MET and was constructed in a
pBABE vector. LNA-miR-34a-5p miR was provided by
Exiqon. The Lipofectamine RNAiMAX (Invitrogen) or Li-
pofectamine 2000 (Invitrogen) were used for transfection
experiments.
Cell lines
CAL27 (CRL-2095) was obtained from ATCC and main-
tained in Dulbecco’s minimal essential medium
(DMEM). HTB-43 was obtained from ATCC and main-
tained in ATCC-formulated Eagle’s Minimum Essential
Medium (EMEM). HCSS-4 (CRL-1582) was obtained
from ATCC and maintained in ATCC-formulated
RPMI-1640 Medium. THP-1 (TIB-202™) was obtained
from ATCC and maintained in ATCC-formulated RPMI.
RAW 264.7 macrophages (ATCC TIB-71) were obtained
from ATCC and cultured in DMEM. All cells were sup-
plemented with 10% fetal bovine serum, 100 U/mL peni-
cillin and 100 mg/mL streptomycin and incubated at
37 °C in 5% CO2.
Wu et al. Journal of Experimental & Clinical Cancer Research           (2021) 40:70 Page 5 of 16
RNA immunoprecipitation (RIP)- qPCR (RIP-qPCR)
Cells were cross-linked and lysed in IP buffer supple-
mented with phosphatase/protease inhibitors and RNase
inhibitor. Cell lysates were sonicated and 100 μg of total
protein was incubated with Ago2 antibody or mouse
IgG (non-specific control), the lysates were incubated
overnight with either 10μg/ml of ChIP-grade anti-Ago2
or mouse IgG in 4 °C for 90 min, followed by addition of
Protein A/G PLUS-Agarose beads and incubation for 80
min. After washing, the eluted RNA samples were fur-
ther purified with TRI reagent and subjected to TaqMan
MicroRNA Assay and qRT-PCR analysis to detect miR-
34a-5p and MET, respectively. Data was normalized
based on the total input.
Flow cytometry
A flow cytometry panel consisting of Lin-1, CD45,
CD11b, F4/80, and CD274 (PDL1) was used for quantifi-
cation and characterization of TAMs. Tumor cells were
dissociated using a gentleMACS™ Tissue dissociator
(Miltenyi) and tumor dissociation kit (Miltenyi) as rec-
ommended by the manufacturer. For intracellular stain-
ing of Vimentin and phospho-STAT3 (p-STAT3), cells
were prepared using the Fix and Perm Kit as recom-
mended by the manufacturer (Invitrogen). Antibody-
capture beads (CompBeads, BD Biosciences) were used
as single-color compensation controls. Cytometer cali-
bration was performed daily by the use of rainbow fluor-
escent particles (BD Biosciences), after acquiring
unstained and single-color control samples to calculate
the compensation matrix. Data were analyzed using FCS
Express software.
Statistical analysis
Student t-tests were performed to compare miR-34a ex-
pression level between classes in TCGA data, with P <
0.05 considered significant. To identify mRNA expres-
sion patterns that significantly correlate with miR-34 ex-
pression, a Pearson’s correlation was performed, and p-
values were corrected using false discovery rate (FDR)
and Bonferroni methods. For experimental data, Para-
metric Student’s t test or Mann-Whitney U test were
performed for comparing two groups. Data are demon-
strated as mean ± standard error of mean (SEM) or
standard deviation (SD). P values less than 0.05 were
considered as statistically significant.
Results
miR-34a is downregulated in different cancers, including
breast cancer, lung cancer, bladder cancer, and pancre-
atic cancer [12, 37, 38]. We analyzed the expression of
miR-34a in TCGA pan-cancer tumor samples. As miR-
34a is a transcriptional target of P53, we compared miR-
34 levels in cases with and without p53 mutation and
found significantly lower miR-34a expression in p53 mu-
tated cases compared to p53 wild-type (WT) cases (P <
0.001) (Fig. 1a). Similarly, in a squamous cell carcinomas
(SCCs) and HNSCC specific analysis, we found a signifi-
cantly lower expression of miR-34a in cases with p53
mutation (P < 0.001) (Fig. 1b and c). miR-34a is located
on chromosome arm 1p, and 1p deletion in non-
mutated p53 cases was associated with a lower level of
miR-34a in the pan-cancer analysis (P < 0.0001) (Fig. 1d).
Chromosome 1p deletion was associated with a lower
level of miR-34a in SCCs (P < 0.001) (Fig. 1e), lung squa-
mous cell carcinoma (P < 0.05) (Fig. 1f), and HNSCC
cases (non-significant (N.S)) (Fig. 1g). No statistically
significant differences of miR-34a expression were de-
tected between gain of chromosome 1p or WT chromo-
some 1p (Fig. 1d-g).
We next assessed the gene expression correlations
with miR-34a expression in HNSCC patients in the
TCGA dataset. For each mRNA, we calculated a Pearson
correlation coefficient measuring its correlation with
miR-34a expression, with Bonferroni-corrected p-values
(Supplemental Table 1A). The correlation coefficients
with a Bonferroni p-value below 0.01 were assessed for
gene set enrichment analysis (GSEA) in the hallmark, and
positional gene sets using the GSEA pre-ranked algorithm
[39]. The epithelial-mesenchymal transition (EMT) hall-
mark pathway was the top anti-correlation (Fig. 1h, Sup-
plementary Tables 1B and 1C, Supplementary Fig. 1),
including genes such as SNAI2, ZEB1, ZEB2, TWIST2,
and TGFB1. The EMT pathway is down-regulated when
miR-34a expression is high, consistent with possible role
for miR-34a in inhibition of this pathway.
The sequences of mature miR-34a-3p (passenger
strand) and miR-34a-5p (guide stand) are reported to be
conserved among species [40]. Bioinformatics sequence
analysis revealed that the MET 3′ UTR has a binding
motif for both miR-34a-3p and miR-34a-5p with high
stability (mirSVR score of − 0.9210 and PhastCons score
of 0.7245 for miR-34a-5p and miRSVR score of − 1.1609
and PHastCons score of 0.7019 for miR-34a-3p) (Fig. 2a,
b). mirSVR score ≤ − 0.1 and conserved sites indicated
by PhastCOns score > 0.57 were reported as a high pre-
dictor of miR-mRNA interaction [41]. We analyzed
levels of miR-34a-3p and miR-34a-5p in our cohort of
primary HNSCC tumor samples compared to the adja-
cent tissue (n = 42). Levels of both miR-34a-5p and miR-
34a-3p were decreased in tumor tissue compared to nor-
mal tissue (P < 0.05) (Fig. 2c and d). miR-34a levels in
plasma isolated from HNSCC patients (n = 28) were also
lower than in plasma from patients without HNSCC
(P < 0.05) (n = 28; Fig. 2e and f). Moreover, levels of
miR-34a-5p and miR-34a-3p were significantly lower in
the circulating exosomes of patients with HNSCC com-
pared to cancer-free patients (P < 0.05) (Fig. 2g and h).
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Checking for absolute quantification of miR-34a-3p
and miR-34a-5p in cancerous and healthy tissue, we
found about a 50% reduction in miR-34a-5p and miR-
34a-3p copy numbers in cancer tissue compared to the
normal keratinocytes and normal tissue (Supplementary
Fig. 2). However, the miR-34a-3p copy number was
overall much lower than miR-34a-5p, which could be
attributed to lower stability of the passenger strand in
miR biogenesis [42].
As our bioinformatics prediction suggested direct tar-
geting of MET by miR-34a-5p, we investigated MET ex-
pression in HNSCC samples. In immunohistochemistry
of an oral squamous cell carcinoma, MET was highly
expressed in oral squamous cell carcinoma/HNSCC
cases, but not in oral dysplasia and normal tissue
(Fig. 3a). Quantitative scoring of immunohistochemistry
showed that the percentage of MET positive cells are
significantly increased in oral squamous cell carcinoma
(HPV−) compared to oral dysplasia and normal tissue
(Fig. 3b). We also found an inverse association between
MET expression and miR-34a-5p in HNSCC tumors
(Fig. 3c). Consistently, we found a significant negative
correlation between the expression of MET and miR-
34a-5p in HNSCC cases of TCGA data (both HPV+ and
HPV-) (Bonferroni corrected P < 0.0001) (Fig. 3d). These
correlations were likely not due to MET copy number
variation (CNV); CNV for MET in HNSCC was so rare
that only 4 out of 497 HNSCC samples in TCGA had
high MET amplification. In addition, analysis of HNSCC
samples with no MET copy number alteration still
showed a significant negative correlation between miR-
34a expression and MET expression (P < 0.0001) (Sup-
plemental Fig. 3). High expression of MET was associ-
ated with significantly lower survival in HNSCC cases,
controlling for age, gender, race, and stage (HR: 1.65,
95% CI: 1:1–1.47), p = 0.037) (Supplementary Table 2).
Cumulative survival analysis showed that HPV+ cases
with high expression of MET (upper quartile) have sig-
nificantly less cumulative survival (HR: 1.83; p = 0.01)
compared to lower quartile (Fig. 3e). There was no cor-
relation between MET expression and survival of HPV−
tumors in cumulative survival analysis.
We next studied the interaction of miR-34a-5p with
MET in HNSCC cell lines. To investigate the direct
Fig. 1 p53 mutation and chr1p deletion correlate with decreased miR-34a expression. a through c: miR-34a expression versus p53 mutation
status in patient tumors across 33 cancer types in the cancer genome atlas (TCGA) pan-cancer dataset (n = 9151) (a), squamous cell carcinomas
(SCCs) (n = 1293) (b), or head and neck squamous cancers (HNSCCs) (n = 490) (c). d through g): miR-34a expression versus chromosome 1p copy
number in p53 WT tumors, across cancer (n = 7792) (d), across SCCs (n = 380) (e), in lung squamous cell carcinomas (n = 57) (f), or HNSCCs (n =
141) (g). h Genes whose expression significantly correlated with miR-34a expression were analyzed by gene set enrichment analysis (GSEA) in
HNSCC samples (n = 497). The plot shows the top enriched hallmark pathway, Epithelial-Mesenchymal Transition (EMT). Y-axis is the GSEA
enrichment score. The X-axis is a list of genes ranked by differential expression correlation with miR-34a, with black bars representing genes in
the EMT gene set. Data is presented in box and whisker plots, with whiskers representing minimum and maximum. * indicates p < 0.05; ***
indicates p < 0.001
Wu et al. Journal of Experimental & Clinical Cancer Research           (2021) 40:70 Page 7 of 16
interaction of miR-34a-5p with MET mRNA, we per-
formed pulldown experiments with biotinylated miR-
34a-5p or negative control probes and quantified levels
of mRNA in the pulldown by qRT-PCR. We observed a
dose-dependent enrichment of MET mRNA with miR-
34a-5p probes suggesting a direct interaction (Fig. 4a).
miRs exert their gene expression regulatory function
through translational inhibition or transcript degradation
via Argonaute 2 (Ago2)-catalyzed cleavage [43]. Thus,
we assessed the association of Ago2 with miR-34a-5p
and MET to determine whether miR-34a was recruiting
AGO2 to MET mRNA. Overexpression of miR-34a-5p
by plasmid followed by anti-Ago2 CHIP and RNA-
binding protein immunoprecipitation (RIP)-qPCR on the
whole cell lysate showed a complex of MET, miR-34a-5p
with Ago2 in CAL27 cells. (Fig. 4b&c). Luciferase assay
Fig. 2 miR-34 is downregulated in head and neck cancer (HNSCC) and targets proto-oncogene MET. a Sequences of the mature miR-34a-5p and
miR-34a-5p in humans and mice. b Bioinformatic analysis suggested direct interaction of both the miR-34a guide strand (hsa-miR-34a-5p) and the
passenger strand (hsa-miR-34a-3p) the 3’UTR of MET mRNA. c through h: Expression of miR-34a-3p and miR-34a-3p were quantified by the
TaqMan microRNA Assay in HNSCC tumor samples and matched controls (n = 42) (c and d), HNSCC and healthy plasma (e and f) and exosomes
isolated from HNSCC patients and healthy subjects (n = 28) (g and h). 2-ΔΔCT method was used for relative expression. Data was normalized to
RNU48 or spike-in cel-mir-39. Data is presented as mean ± SD. * indicates p < 0.05
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further confirmed the direct interaction of miR-34a seed
sequence with the MET 3’UTR, where a significant de-
crease in luciferase activity was detected when CAL27
cells were co-transfected with the WT 3’UTR of MET
and not a mutated 3’UTR (Fig. 4d).
Next, we assessed whether miR-34a-5p level in the
HNSCC cell lines. The level of miR-34a-5p was down in
all the HNSCC cell lines examined compared to oral
keratinocytes (P < 0.001) (Fig. 4e), and the mRNA levels
of MET were elevated in those cell lines (P < 0.001) (Fig.
4f). As a more direct test to assess the effect of higher
miR-34a on MET levels, we used a miR-34a-5p mimic, a
synthetic miR. Introduction of the miR-34a-5p mimic in
CAL27 cells resulted in a decrease of MET mRNA and
protein levels (Fig. 4g-i).
miR-34a has been suggested to play a significant role
in cancer cell proliferation, apoptosis, and migration
[43]. Thus, we further investigated the role of miR-34a
in head and neck carcinogenesis using the miR-34a-5p
mimic. Upon administration of the mimic in two differ-
ent HNSCC cell lines (HTB-43, CAL27), measurement
of annexin V and propidium iodide staining demon-
strated an increase in the percentage of early apoptotic
cells as well as suppression of MET expression (Fig. 5a-
c). Introduction of the miR-34a-5p mimic led to dose-
dependent inhibition of proliferation in the CAL27 cell
line (P < 0.05) (Fig. 5d, e) and HCSS-4 cell line (Supple-
mentary Fig. 4). To assess whether the anti-apoptotic
effects of miR-34a-5p are at least partially exerted via
MET signaling, we inhibited miR-34a in CAL27 cells
using anti-miR technology (Fig. 5f) and treated cells with
MET siRNA. Suppression of MET inhibited proliferation
(Fig. 5g).
To determine whether any of the effects of MET over-
expression are dependent on miR-34a-5p, we generated
CAL27 cells with MET overexpression (Fig. 6a). MET
overexpression-induced cell growth and proliferation
was attenuated by the miR-34a-5p transient introduction
(Fig. 6b). In addition, our rescue experiment demon-
strated that miR-34a-5p can reverse the anti-apoptotic
effect of MET overexpression (Fig. 6c).
As it has previously been shown that activated MET
induces tumor invasion via phosphorylation of STAT3,
we assessed levels of phospho-STAT3 (p-STAT3) and
found decreased p-STAT3 after the introduction of
miR-34a-5p mimic in CAL27 cell lines (Fig. 6d). As our
bioinformatics analysis in TCGA tumors showed negative
correlations of miR-34a-5p with the expression of
epithelial-to-mesenchymal transcription factors such as
SNAI2, ZEB1, ZEB2, and TWIST2 and presented in Fig.
1g, we assessed expression changes of epithelial and mesen-
chymal markers upon miR-34a-5p overexpression in
HNSCC cell lines. Interestingly, the administration of miR-
34a-5p led to a decreased mRNA expression of the mesen-
chymal marker vimentin and increased expression of epi-
thelial marker CDH1 in CAL27 and HTB-43 (Fig. 6e & f),
Fig. 3 Levels of miR-34a negatively correlate with MET, and MET is overexpressed in head and neck squamous cancer (HNSCC). a
Immunohistochemistry of MET expression in normal tissue, dysplastic tissue, and HNSCC tissue. b The percentage of MET positive cells were
quantified in normal tissue, oral dysplasia, and HNSCC. c Levels of miR-34a-5p levels were quantified in high MET mRNA HNSCC cases versus low
MET mRNA HNSCC cases. d Correlation of MET expression and miR-34a levels in over 497 HNSCC cancers in the TCGA dataset (R = -0.38, p <
0.0001) (e) Cumulative survival of HPV+ HNSCC cases with high MET mRNA compared to low MET mRNA in TCGA database (n = 497). Data
represent results of at least three independent experiments. * indicates p < 0.05. **** indicates P < 0.0001
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consistent with the inhibition of EMT. Similarly, the admin-
istration of miR-34a-5p led to a decreased in Vimentin pro-
tein expression and an increase in CDH1 protein
expression.
In order to determine the efficacy of restoring miR-
34a-5p level as a therapeutic strategy, we used an LNA-
miR-34a-5p mimic. LNA-miR-34a-5p was injected intra-
peritoneally (i.p) into an orthotopic xenograft mouse
model of oral cancer (Fig. 7a). Tumor growth was sig-
nificantly attenuated in the mice that received the LNA-
miR-34a-5p mimic compared to those that received the
control mimic or vehicle (Fig. 7b). The level of miR-34a-
5p was significantly increased in the tumors of mice that
received LNA-miR-34a-5p (Fig. 7c). The level of MET
was significantly deceased in the lysate of tumors iso-
lated from these mice as well (Fig. 7d). Isolation of
tumor epithelial cells and TAMs showed significant in-
creases in the level of miR-34a-5p in both cell types after
administration of LNA-miR-34a-5p mimic (Fig. 7e, f).
The mesenchymal marker vimentin was significantly de-
creased in the treatment group, indicating suppression
of EMT by miR-34a-5p (Fig. 7g, h). Flow cytometry
analysis on TAMs showed a decrease in the
PDL1+TAMs (CD11b + F4/80+) in the group that re-
ceived LNA-mir-34a-5p treatment (Fig. 7i). PDL1 is re-
ported to be direct target of miR-34a-5p [44].
Consistently, a luciferase assay confirmed the direct
interaction of miR-34a-5p seed sequence with the PDL1
3’UTR, where a significant decrease in luciferase activity
was detected when RAW macrophages were co-
transfected with the WT 3’UTR of PDL1 (Fig. 7j). Taken
together, these data support the mechanistic connection
of miR-34a-5p in suppressing oncogenic MET and re-
storing tumor immunity through targeting PDL1.
As the tumor microenvironment is composed of dif-
ferent cell types and miR-34a plays a role in tissue
homeostasis, we evaluated the correlation between miR-
34a expression and cellular subtypes in TCGA data. The
cellular subtype estimates were generated by xCell.
Among the top hits, higher expression of miR-34a was
correlated with a significantly higher level of pro-B cells
[p (FDR) = 4.42E-13], CD8 naïve T-cells [p (FDR) =
0.008245842] and Th1 cells [p (FDR) = 3.83E-7] in
HNSCC tumors (Supplementary Table 3).
Fig. 4 miR-34a directly interacts with MET mRNA and downregulates MET. a RNA was isolated from cells, biotin-based pull-down probe for miR-
34a-5p or negative control probe at different concentrations to assess interaction of miR-34a-5p with MET in CAL27 cells was used. The
enrichment of MET was quantified by qRT-PCR. b and c The miR-34a-5p overexpressing CAL27 cells were subjected to an anti-Ago2 CHIP assay.
Levels of MET and miR-34a-5p were quantified by RIP-qPCR. d Dual-luciferase assay was performed in cells transfected with miR-34a-5p mimic or
a control miR mimic and a luciferase reporter construct encoding the luciferase gene fused either to a mutated MET 3′ UTR (MUT) or a wild-type
MET 3′ UTR (WT). e and f MET expression and miR-34a-5p expression in HNSCC cell lines were quantified by a TaqMan microRNA assay. g miR-
34a-5p mimic was introduced to CAL27 cells by electroporation (25 nM). Levels of miR-34a-5p was quantified by a TaqMan microRNA assay after
12 h. h MET mRNA expression was quantified 24 h after over-expression of miR-34a-5p mimic. i Western blot measuring MET protein expression
with and without expression of miR-34a-5p mimic. All experiments were performed in CAL27 cells. All experiments were performed in triplicate.
Data represent results of at least three independent experiments. Data is presented as mean ± SD.* indicates p < 0.05
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Discussion
MicroRNAs play an important role in the progression of
HNSCC tumorigenesis and growth [27, 28, 45–47]. It
has been suggested that specific miRs could act as a mo-
lecular diagnostic tool for HNSCC [48, 49], and miR-
based therapy could potentially be a rational approach
for the therapeutic targeting of HNSCC [50]. Identifying
novel targets that would be efficient in HNSCC therapy
is critical. In the present study, for the first time, we in-
vestigated the role of the miR-34a-MET axis in the
pathogenesis of HNSCC. Our analysis of TCGA data
demonstrated that downregulation of miR-34a is associ-
ated with p53 mutation and chromosome arm 1p dele-
tion in HNSCC and lung squamous cell carcinoma.
Additionally, higher levels of miR-34a-5p were corre-
lated with lower levels of key transcription factors of
EMT. We found significantly decreased levels of miR-
34a-5p in tumor tissue and circulation of patients with
HNSCC. We found that miR-34a-5p acts as a tumor
suppressor, directly represses the proto-oncogene MET,
and modulates cell proliferation. Lastly, our work dem-
onstrates the role of miR-34a in maintaining tumor im-
munity, as administration of LNA-miR-34a-5p mimic
resulted in a decrease in the percentage of PDL1+TAMs,
which are reported to have pro-tumorigenic and im-
munosuppressive activity [51, 52].
miR-34a is down-regulated in many cancers [43, 53–
55], and there are several hypotheses that explain this
down-regulation [44, 56–58]. By leveraging the TCGA
dataset, we demonstrated two possible mechanisms of
miR-34a-5p down-regulation in cancer. Consistent with
previous work, p53 mutation correlates with decreased
expression of miR-34a, suggesting miR-34a as a tran-
scriptional target of p53. In addition, miR-34a is located
Fig. 5 miR-34a over-expression induces early apoptosis, prevents tumor proliferation, and inhibits tumor growth in vivo. a Representative flow
cytometry plot of annexin V (FITC) versus propidium iodide in control mimic treated cells or miR-34a-5p treated HTB-42 cells (25 nM, 48 h). Early
apoptotic cells were defined as propidium iodide low and Annexin-V high. b, c The early apoptosis detection assay determined the percentage
of early apoptotic cells in 2 different head and neck squamous cell lines (HTB-43 and CAL27 cells), and MET expression was confirmed by western
blot. d The level of miR-34a-5p expression was determined by a TaqMan microRNA assay, 12 h post electroporation of miR-34a mimic or control
mimic (25 nM). e miR-34a-5p mimic (25 nM or 50 nM) was administered to cells at day 0, and proliferation was measured using MTT reagent to assess
the effect of miR-34a on the proliferation of CAL27 cells. f and g Anti-LNA-miR-34a (miR-34a-5p inhibitor) was administered to CAL27 cells and a
TaqMan microRNA Assay was used to quantify levels of miR-34a-5p. MET siRNA (20 nM) or scramble siRNA (20 nM) were introduced to CAL27 cells
which received miR-34a-5p inhibitor by Lipofectamine RNAiMAX and cell proliferation was quantified by MTT assay. All experiments performed at least
in triplicate. Data represent results of at least three independent experiments. Data is presented as mean ± SD.* indicates p < 0.05
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on chromosome 1p, a chromosome arm that is fre-
quently deleted in cancer [13]. We also demonstrated
that chromosome 1p deletion correlates with decreased
miR-34a expression. This is not surprising, as DNA copy
number generally correlates with gene expression, but
also provides another explanation for decreased miR-34a
in HNSCC. In addition, these findings suggest that
chromosome arm-level deletion could serve as a bio-
marker for response to miR-34a-based therapeutic ap-
proaches. We are actively pursuing aneuploidy as a
biomarker for drug response, including for miR-34a and
other miRs. Interestingly, the effect of copy number on
miR-34a expression is masked by p53 mutation; if p53 is
mutated, there is no correlation between chromosome
1p copy number and miR-34a expression. These data
are consistent with trans transcriptional regulation serv-
ing a dominant role over cis DNA levels.
Our mechanistic experiments showed that miR-34a
directly interacts with the proto-oncogene MET and at-
tenuates the MET signaling axis by posttranscriptional
gene regulation in cancer cells. Activating point
mutations of MET and MET amplification have been re-
ported in several cancer types, including gastric cancer
[59], breast cancer [60], hepatocellular carcinoma [61,
62], and non-small cell lung cancer [63, 64]. MET plays
an important role in the occurrence, development, inva-
sion, and metastasis of malignant tumors [65–67]. While
MET is a validated drug target in lung cancer, the best
biomarker strategy for enrichment of a susceptible pa-
tient population still remained undefined [63]. Activa-
tion of HGF/MET signaling correlates with increased
recurrence rates and poor prognosis in HNSCC [68, 69].
MET is a potential novel therapeutic target for HNSCC
and a greater-than-additive inhibition of cell growth was
observed when combining a MET inhibitor with cis-
platin or erlotinib [70].
In preclinical HNSCC models, MET expression and
activation have also been shown to be associated with
resistance to anti-EGFR therapeutics. Novoplansky et al.
reported an association between MET amplification and
overexpression with HNSCC progression, and poten-
tially overactive MET played a causative role in the
Fig. 6 The anti-tumorigenic effect of miR-34a is dependent on MET, and miR-34a-5p inhibits epithelial mesenchymal transition (EMT). a MET
vector or control vector (pBABE) were introduced to CAL27 cells and levels of MET mRNA expression were quantified by RT-qPCR. b miR-34a-5p
(25 nM) mimic was administrated to the MET overexpressing CAL27 cells and cell proliferation was measured after 24 h using MTT assay. MET
signaling was stimulated with HGF (20 ng/ml). c Percentage of early apoptotic cells were determined by Annexin V and PI in MET overexpressing
CAL27 cells with and without introduction of miR-34a-5p mimic. MET signaling was stimulated with HGF (20 ng/ml). d Effect of miR-34a-5p on
STAT3 protein phosphorylation (shaded line: control; open line: HGF (20 ng/ml); gray line: HGF (20 ng/ml) + miR34a-5p mimic). e, f Relative mRNA
expression of epithelial marker (CDH1) and mesenchymal marker (Vimentin) were quantified 48 h after introduction of the miR control mimic or
miR-34a-5p mimic by Lipofectamine RNAiMAX in CAL27 cells. RT- qPCR data was normalized using 18 s. g Protein expression of CDH1 and
Vimentin were determined after 48 h administration of miR-34a-5p mimic or control mimic in CAL27 cells using western blot. Data represent
results of at least three independent experiments. Data is presented as mean ± SD. * indicates p < 0.05. *** < 0.001
Wu et al. Journal of Experimental & Clinical Cancer Research           (2021) 40:70 Page 12 of 16
development of resistance to cetuximab in HNSCC [71].
Interestingly, MET induces MAPK re-activation in all
tested HNSCC models, and blocking of MAPK with a
MET inhibitor re-sensitized the HGF-stimulated tumor
cells to cetuximab [71]. Similarly, MET knock down sen-
sitized two cetuximab resistant non-small cell lung
adenocarcinoma cell lines, LXFA 526 L and LXFA 1647
L, to EGFR inhibition [69]. We found high expression of
MET throughout the entire epithelium in oral cancer
compared to partial staining in oral dysplastic lesions
and no expression in normal tissue. The mechanistic
role of MET in the transformation of pre-cancerous le-
sions to cancerous lesions should be further investigated
in future studies.
Direct interaction of mir-34a-5p with PDL1 has been
reported previously [44]. The role of the PDL1- PD1 axis
in facilitating tumor escape from immune control has
led to an active therapeutic target in multiple cancer
types [72, 73]. However, the fact that PDL1 is expressed
not only in cancer cells but also in immune cells with
the highest abundance in TAMs has only been recently
reported [74–76]. TAMs are one of the major cell popu-
lations in the tumor microenvironment [77], and they
express the vast majority of PDL1 in tumors. The level
of PDL1 expression in TAMs could determine the effi-
cacy of PDL1 pathway blockade [51, 74]. TAMs that ex-
press PDL1 can suppress T cells in the tumor
microenvironment and contribute to tumor immune
evasion [78, 79].
The pleiotropic nature of miRs and their involvement
in all cancer hallmarks make them particularly attractive
drug targets for cancer treatment. A challenge of miR-
based therapy is the delivery of miRs in the right dose to
the target tissue. Different drug delivery vehicles have
been proposed for miR delivery, including liposomes and
exosomes. Liposomes are immunogenic, subject to rapid
Fig. 7 Administration of miR-34a-5p mimic inhibit tumors growth and PDL1 expressing tumor associated macrophages (TAMs). a 2 × 106 HTB-43
cells were injected to the tongue of nude mice. LNA-control mimic or LNA-miR-34a mimic were once a week (20 mg/kg; intraperitoneal) for two
weeks, starting 10 days after tumor cell injections. Mice were euthanized after 20 days and epithelial cell and TAMs were isolated after tissue
dissociation using a tumor dissociation kit and isolation of cells with magnetic beads (CD326 (EpCAM) for tumor epithelial cells and CD11b for
TAMs). A representative histology of HTB-43 xenograft tumor is included. b Tumor volume was measured by caliper (N = 8 per group). c Level of
miR-34a-5p was quantified in tumor lysate using a TaqMan microRNA assay (N = 8 per group). d Levels of MET were assessed in tumor lysates of
mice that received the LNA control mimic or the LNA-miR-34a mimic. e, f Levels of miR-34a-5p was quantified in isolated tumor epithelial cells
after isolation by Anti-EpCAM magnetic beads (n = 8 per group) and TAMs after isolation by Anti-CD11b magnetic beads (n = 8 per group). g The
percentage fold over control of Vimentin expression in mice that received the LNA-control miR or LNA-miR-34a-5p mimic (n = 6 mice per group)
measured by qRT-PCR. h Levels of Vimentin protein expression were quantified in tumor cells with rat anti-mouse vimentin APC-conjugated
antibody. Filled histogram represents the mice that received LNA-control miR, and open histogram represents the mice that received LNA-miR-
34a-mimic. i Percentage of PDL1 expressing TAMs (defined as CD45+CD11b+F4/80+ cells) were quantified by flow cytometry (n = 8 per group). j
Luciferase activity in cells transfected with miR-34a-5p mimic or a control miR mimic and a luciferase reporter construct encoding the luciferase
gene fused either to the a mutated PDL1 3′ UTR (MUT) or a wild-type PDL1 3′ UTR (WT) in RAW 264.7 cells. Data represent results of at least three
independent experiments. * indicates p < 0.05. Data is presented as mean ± SD. * indicates p < 0.05; *** indicates p < 0.001
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clearance by the immune system after administration
[80]. In contrast, exosomes, naturally occurring nanove-
sicles, are not immunogenic and can be used effectively
for miR-based therapy [81]. Another strategy is the
chemical modification of miR-mimics or inhibitors to in-
duce higher stability and cell penetration. In accessible
solid tumors, intra-tumoral injections of miR-based ther-
apies into the pathogenic site could improve efficacy and
minimize side effects [82]. In the present study, we
showed that restoration of miR-34a-5p using LNA-
miR34-5p could inhibit tumor growth and progression
and restore anti-tumor immune function in HNSCC.
Conclusions
This study presents strong evidence that miR-34a-5p
acts as a tumor suppressor and physically interacts with
and functionally targets the proto-oncogene MET. miR-
34a-5p overexpression may have a potential therapeutic
benefit in HNSCC via MET inhibition and restoration of
anti-tumor immunity. In particular, miR-34a-5p overex-
pression might be useful as adjuvant therapy or mono-
therapy in HNSCC.
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